{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "c6ef35bd-33af-55cc-ab6a-b5c922e14c24", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0001", "source_id": "SOURCE-20251114-1122", "category": "prediction", "content": "The next Genentech will not resemble the previous one.", "line_start": 14, "line_end": 15, "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.7, 0.3, 0.1, 0.8, 0.1, 0.4], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Prediction", "name": "The next Genentech will not resemble the previous one.", "content": "The next Genentech will not resemble the previous one.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 14, "line_end": 15, "atom_id": "ATOM-SOURCE-20251114-1122-0001"}, "metadata": {"category": "prediction", "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.7, 0.3, 0.1, 0.8, 0.1, 0.4], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "1e2a794f-dbd9-59ee-9a35-0f56561d0863", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0002", "source_id": "SOURCE-20251114-1122", "category": "claim", "content": "The cost of drug development has exploded to $2.5 billion per approval, driven by \"three horsemen\" strangling the process.", "line_start": 15, "line_end": 17, "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.2, 0.7, 0.1, 0.1, 0.1, 0.8], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Claim", "name": "The cost of drug development has exploded to $2.5 billion per approval, driven b", "content": "The cost of drug development has exploded to $2.5 billion per approval, driven by \"three horsemen\" strangling the process.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 15, "line_end": 17, "atom_id": "ATOM-SOURCE-20251114-1122-0002"}, "metadata": {"category": "claim", "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.2, 0.7, 0.1, 0.1, 0.1, 0.8], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "1238bd99-ad62-5a23-812e-f46b7e1e3eb7", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0003", "source_id": "SOURCE-20251114-1122", "category": "claim", "content": "Investigator-initiated trials in Shanghai are rewriting the competitive playbook in biotech faster than American founders can file Investigational New Drug (IND) applications.", "line_start": 17, "line_end": 20, "chaperone": {"context_type": "anecdote", "argument_role": "evidence", "tension_vector": [0.4, 0.6, 0.2, 0.3, 0.2, 0.6], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Claim", "name": "Investigator-initiated trials in Shanghai are rewriting the competitive playbook", "content": "Investigator-initiated trials in Shanghai are rewriting the competitive playbook in biotech faster than American founders can file Investigational New Drug (IND) applications.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 17, "line_end": 20, "atom_id": "ATOM-SOURCE-20251114-1122-0003"}, "metadata": {"category": "claim", "chaperone": {"context_type": "anecdote", "argument_role": "evidence", "tension_vector": [0.4, 0.6, 0.2, 0.3, 0.2, 0.6], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "bf451d46-a49d-5a30-aa5c-f08fa94642f5", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0004", "source_id": "SOURCE-20251114-1122", "category": "claim", "content": "The infrastructure that historically built monoclonal antibodies is now a commodity threatening to hollow out the biotech industry.", "line_start": 20, "line_end": 22, "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.3, 0.6, 0.2, 0.2, 0.1, 0.7], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Claim", "name": "The infrastructure that historically built monoclonal antibodies is now a commod", "content": "The infrastructure that historically built monoclonal antibodies is now a commodity threatening to hollow out the biotech industry.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 20, "line_end": 22, "atom_id": "ATOM-SOURCE-20251114-1122-0004"}, "metadata": {"category": "claim", "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.3, 0.6, 0.2, 0.2, 0.1, 0.7], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "19e45f86-56b3-567d-95dd-d5fda3f88c2e", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0005", "source_id": "SOURCE-20251114-1122", "category": "praxis_hook", "content": "To compete in biotech, the path forward demands inventing medicines that are literally impossible to make without tools that do not yet exist.", "line_start": 22, "line_end": 24, "chaperone": {"context_type": "method", "argument_role": "claim", "tension_vector": [0.8, 0.2, 0.1, 0.7, 0.6, 0.3], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "PraxisHook", "name": "To compete in biotech, the path forward demands inventing medicines that are lit", "content": "To compete in biotech, the path forward demands inventing medicines that are literally impossible to make without tools that do not yet exist.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 22, "line_end": 24, "atom_id": "ATOM-SOURCE-20251114-1122-0005"}, "metadata": {"category": "praxis_hook", "chaperone": {"context_type": "method", "argument_role": "claim", "tension_vector": [0.8, 0.2, 0.1, 0.7, 0.6, 0.3], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "13b79350-aeac-5134-98ff-33db8ee97f04", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0006", "source_id": "SOURCE-20251114-1122", "category": "concept", "content": "Eroom's Law describes why drug development costs $2 billion and takes longer than ever.", "line_start": 29, "line_end": 30, "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.3, 0.7, 0.1, 0.1, 0.1, 0.8], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Concept", "name": "Eroom's Law describes why drug development costs $2 billion and takes longer tha", "content": "Eroom's Law describes why drug development costs $2 billion and takes longer than ever.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 29, "line_end": 30, "atom_id": "ATOM-SOURCE-20251114-1122-0006"}, "metadata": {"category": "concept", "chaperone": {"context_type": "consensus", "argument_role": "claim", "tension_vector": [0.3, 0.7, 0.1, 0.1, 0.1, 0.8], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "d3892753-c770-5660-9ab7-0a486a13c4d5", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0007", "source_id": "SOURCE-20251114-1122", "category": "claim", "content": "China possesses a significant speed and cost advantage in biotech, creating a geographic arbitrage problem for other nations.", "line_start": 31, "line_end": 32, "chaperone": {"context_type": "consensus", "argument_role": "evidence", "tension_vector": [0.4, 0.6, 0.2, 0.3, 0.2, 0.7], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Claim", "name": "China possesses a significant speed and cost advantage in biotech, creating a ge", "content": "China possesses a significant speed and cost advantage in biotech, creating a geographic arbitrage problem for other nations.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 31, "line_end": 32, "atom_id": "ATOM-SOURCE-20251114-1122-0007"}, "metadata": {"category": "claim", "chaperone": {"context_type": "consensus", "argument_role": "evidence", "tension_vector": [0.4, 0.6, 0.2, 0.3, 0.2, 0.7], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "8500e404-6eef-52bd-9933-ff7ebce8189a", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0008", "source_id": "SOURCE-20251114-1122", "category": "prediction", "content": "AI in drug development has the potential to reduce the cost of a $2.5 billion drug to $500 million.", "line_start": 33, "line_end": 34, "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.7, 0.3, 0.1, 0.9, 0.4, 0.3], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Prediction", "name": "AI in drug development has the potential to reduce the cost of a $2.5 billion dr", "content": "AI in drug development has the potential to reduce the cost of a $2.5 billion drug to $500 million.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 33, "line_end": 34, "atom_id": "ATOM-SOURCE-20251114-1122-0008"}, "metadata": {"category": "prediction", "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.7, 0.3, 0.1, 0.9, 0.4, 0.3], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "0d2f4240-b704-504c-90f2-3c8a1d405b13", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0009", "source_id": "SOURCE-20251114-1122", "category": "claim", "content": "GLP-1s are a drug class that has revitalized the biotech industry.", "line_start": 34, "line_end": 35, "chaperone": {"context_type": "consensus", "argument_role": "evidence", "tension_vector": [0.2, 0.8, 0.1, 0.1, 0.1, 0.9], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Claim", "name": "GLP-1s are a drug class that has revitalized the biotech industry.", "content": "GLP-1s are a drug class that has revitalized the biotech industry.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 34, "line_end": 35, "atom_id": "ATOM-SOURCE-20251114-1122-0009"}, "metadata": {"category": "claim", "chaperone": {"context_type": "consensus", "argument_role": "evidence", "tension_vector": [0.2, 0.8, 0.1, 0.1, 0.1, 0.9], "opposes_atom_ids": []}, "extensions": {}}}
{"record_type": "source_atom", "schema_version": "1.0.0", "uuid": "b131dae0-ffe6-5cb9-b00c-130eb3fcde0c", "timestamp": "2026-02-24T00:58:35.070993+00:00", "payload": {"atom_id": "ATOM-SOURCE-20251114-1122-0010", "source_id": "SOURCE-20251114-1122", "category": "prediction", "content": "Aging will be treated before its underlying mechanisms are fully understood.", "line_start": 35, "line_end": 36, "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.6, 0.3, 0.1, 0.8, 0.3, 0.4], "opposes_atom_ids": []}, "extensions": {}}, "source_id": "SOURCE-20251114-1122", "entity_type": "Prediction", "name": "Aging will be treated before its underlying mechanisms are fully understood.", "content": "Aging will be treated before its underlying mechanisms are fully understood.", "confidence": 1.0, "provenance": {"source_id": "SOURCE-20251114-1122", "line_start": 35, "line_end": 36, "atom_id": "ATOM-SOURCE-20251114-1122-0010"}, "metadata": {"category": "prediction", "chaperone": {"context_type": "speculation", "argument_role": "claim", "tension_vector": [0.6, 0.3, 0.1, 0.8, 0.3, 0.4], "opposes_atom_ids": []}, "extensions": {}}}
